Reaction: Trastuzumab deruxtecan to 2 products

Reaction
Reaction type
Not Available
Direction
Major circulating metabolite?
No
Spontaneous?
No
Activity
unknown
References
  1. Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, Chen L, Zhu Y, Guo C, Shi J, Yu D: Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem. 2019 Dec 1;183:111682. doi: 10.1016/j.ejmech.2019.111682. Epub 2019 Sep 6. [Article]
  2. FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Cathepsin BNot AvailableNot Availableimplied
Cathepsin L1Not AvailableNot Availableimplied